Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

被引：0
|
作者：
Megan C. Roberts
Dave P. Miller
Steven Shak
Valentina I. Petkov
机构：
[1] National Cancer Institute,
[2] Genomic Health Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2017年 / 163卷
关键词：
Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [21] Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer
    Gregory S. Calip
    Nadia A. Nabulsi
    Colin Hubbard
    Alemseged A. Asfaw
    Inyoung Lee
    Jifang Zhou
    Jenilee Cueto
    Debanjali Mitra
    Naomi Y. Ko
    Kent F. Hoskins
    Ernest H. Law
    Cancer Causes & Control, 2022, 33 : 793 - 799
  • [22] Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
    Varga, Zsuzsanna
    Sinn, Peter
    Fritzsche, Florian
    von Hochstetter, Arthur
    Noske, Aurelia
    Schraml, Peter
    Tausch, Christoph
    Trojan, Andreas
    Moch, Holger
    PLOS ONE, 2013, 8 (03):
  • [23] An optimized Breast Cancer Index node-positive (BCIN plus ) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR plus ) node-positive breast cancer
    Liefers, G-J.
    Noordhoek, I.
    Zhang, Y.
    Sgroi, D. C.
    Putter, H.
    Treuner, K.
    Wong, J.
    Kranenbarg, E. Meershoek-Klein
    Duijm-De Carpentier, M.
    van de Velde, C.
    Schnabel, C. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S23 - S24
  • [24] Utilizing the Oncotype DX Recurrence Score in the Adjuvant Treatment Management of Node-Positive, Early-Stage Breast Cancer Patients
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    MODERN PATHOLOGY, 2013, 26 : 59A - 59A
  • [25] Utilizing the Oncotype DX Recurrence Score in the Adjuvant Treatment Management of Node-Positive, Early-Stage Breast Cancer Patients
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    LABORATORY INVESTIGATION, 2013, 93 : 59A - 59A
  • [26] Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study
    Fan, Ming
    Cui, Yajing
    You, Chao
    Liu, Li
    Gu, Yajia
    Peng, Weijun
    Bai, Qianming
    Gao, Xin
    Li, Lihua
    RADIOLOGY, 2022, 302 (03) : 516 - 524
  • [27] Clinical outcomes and Oncotype DX Breast Recurrence Score (R) in early-stage BRCA-associated hormone receptor-positive breast cancer
    Layman, Rachel M.
    Lin, Heather
    Barrera, Angelica M. Gutierrez
    Karuturi, Meghan S.
    Yam, Clinton
    Arun, Banu K.
    CANCER MEDICINE, 2022, 11 (06): : 1474 - 1483
  • [28] Impact of the Intermediate Oncotype DX Recurrence Score results on adjuvant treatment recommendations in hormone receptor-positive early breast cancer in a single center.
    De San Vicente, Borja Lopez
    Novas, Patricia
    Galve Calvo, Elena
    Fernandez, Sara
    Arrazubi, Virginia
    Angeles Sala, Maria
    Fernandez, Seila
    Arevalo, Alberto
    Fernando Arango, Juan
    Zumarraga, Ane
    Sande, Laura
    Teresa Perez-Hoyos, Maria
    Abad, Teresa
    Martinez del Prado, Purificacion
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015
    Lu Zhang
    Mei-Chin Hsieh
    Valentina Petkov
    Qingzhao Yu
    Yu-wen Chiu
    Xiao-Cheng Wu
    Breast Cancer Research and Treatment, 2020, 180 : 491 - 501
  • [30] The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia
    Sakata, Shinichiro
    Cronk, Michelle
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (01) : 94 - 95
12345